Completed PHASE2 INTERVENTIONAL 2-arm NCT01480583

GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases (GRABM-B)

A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Sponsor: Angiochem Inc

Conditions Brain Metastases Breast Cancer

Interventions 18F-FLT GRN1005 Trastuzumab

Updated 7 times since 2017 Last updated: Jul 11, 2016 Started: Oct 31, 2011 Primary completion: Jun 30, 2015 Completion: Oct 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01480583, this PHASE2 trial focuses on Brain Metastases and Breast Cancer and remains completed. Sponsored by Angiochem Inc, it has been updated 7 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Angiochem Inc

Data source: Angiochem Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Harvey, United States
• Rockville, United States